US Broker Ratings

Abbott Laboratories (ABT) Stock Analysis: Evaluating Growth Potential with a 5.23% Upside

Abbott Laboratories (NYSE: ABT) stands as a formidable player in the healthcare sector, particularly within the medical devices industry. With a market capitalization of $232.41 billion,..

PureTech Health plc (PRTC) Stock Analysis: Uncovering a 190% Upside in the Biotech Sector

For investors seeking opportunities in the biotechnology sector, PureTech Health plc (PRTC) presents a compelling case with its significant potential upside of 190.03%, as suggested by..

Kamada Ltd. (KMDA) Stock Analysis: Exploring a Promising 114.70% Upside in the Healthcare Sector

Kamada Ltd. (NASDAQ: KMDA), a prominent player in the healthcare sector, is capturing investor attention with a compelling potential upside of 114.70%, as indicated by recent..

COMPASS Pathways (CMPS): Exploring a Potential 306% Upside in the Mental Health Revolution

COMPASS Pathways Plc (NASDAQ: CMPS) is carving a niche in the healthcare sector with its innovative approach to mental health treatment. As a biotechnology company based..

Tilray Brands, Inc. (TLRY) Stock Analysis: Exploring a Potential 191% Upside in the Cannabis Sphere

Tilray Brands, Inc. (NASDAQ: TLRY) is a prominent player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. This Canadian-based company has..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 133.83% Potential Upside in Biotech Innovation

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) is making waves in the biotechnology sector with its innovative approach to tackling cancer resistance mechanisms. With a market capitalization of..

Verve Therapeutics, Inc. (VERV) Stock Analysis: Unveiling a 429% Potential Upside in the Biotech Sector

Verve Therapeutics, Inc. (NASDAQ: VERV), a pioneering entity in the biotechnology sector, is making waves with its innovative approach to gene editing medicines aimed at combating..

SIGA Technologies Inc. (SIGA) Stock Analysis: Navigating a Challenging Revenue Landscape with Promising Valuation Metrics

SIGA Technologies Inc. (SIGA), a significant player in the healthcare sector, is making waves with its specialized focus on the health security market. Known for its..

Sana Biotechnology, Inc. (SANA) Stock Analysis: A Look at Potential 311% Upside

Sana Biotechnology, Inc. (NASDAQ: SANA) is generating significant buzz in the investment community due to an impressive potential upside of over 311%. As a player in..

Abivax SA (ABVX) Stock Analysis: A Biotechnology Gem with a 517.50% Upside Potential

Abivax SA (ABVX), a Paris-based biotechnology company, is making waves in the healthcare sector with its innovative approach to treating chronic inflammatory diseases. Despite the current..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Unlocking an 83.72% Potential Upside in Healthcare Diagnostics

For investors eyeing opportunities in the healthcare sector, Myriad Genetics, Inc. (NASDAQ: MYGN) presents an intriguing proposition. Specializing in molecular diagnostic testing and precision medicine, Myriad..

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring a 311% Potential Upside in CNS Disorder Solutions

Rapport Therapeutics, Inc. (NASDAQ: RAPP) stands as a promising beacon in the biotechnology sector, specializing in the development of groundbreaking small molecule therapies for central nervous..

Arvinas, Inc. (ARVN) Stock Analysis: Unlocking a 158% Upside Potential in Biotechnology

Investors with a keen eye on the biotechnology sector may want to turn their attention to Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company that is..

Cross Country Healthcare, Inc. (CCRN): Investor Outlook on Potential 35% Upside

Cross Country Healthcare, Inc. (NASDAQ: CCRN) has captured investor attention with an enticing potential upside of 35.65%, based on analyst target prices. As a key player..

MBX Biosciences, Inc. (MBX) Stock Analysis: Exploring a Promising 194% Potential Upside

For investors keen on the biotech sector, MBX Biosciences, Inc. (MBX) presents a compelling opportunity with a notable 194% potential upside. As a clinical-stage biopharmaceutical company,..

Opthea Limited (OPT) Stock Analysis: Navigating Biotech Challenges with a -60.90% Potential Downside

Opthea Limited (NASDAQ: OPT), a clinical-stage biopharmaceutical company headquartered in South Yarra, Australia, has firmly placed itself in the spotlight of the biotech sector with its..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 360% Potential Upside in Biotechnology

Relay Therapeutics, Inc. (NASDAQ: RLAY) is capturing investor attention with its substantial potential upside of 360.45%, according to analyst target price projections. A clinical-stage biotechnology company,..

Tourmaline Bio, Inc. (TRML): Unpacking a Potential 237% Upside with Consensus Buy Ratings

Tourmaline Bio, Inc. (NASDAQ: TRML) is capturing investor attention with its remarkable potential upside and unanimous buy ratings from analysts. As a biotechnology player focused on..

Bicycle Therapeutics plc (BCYC) Stock Analysis: Exploring a Transformative 201.99% Upside Potential

Bicycle Therapeutics plc (NASDAQ: BCYC) is a UK-based biotechnology company renowned for its innovative approach to developing a new class of medicines—Bicycle toxin conjugates (BTCs). The..

Humacyte, Inc. (HUMA) Stock Analysis: Exploring a 240% Potential Upside in Biotechnology

In the often volatile world of biotechnology, Humacyte, Inc. (NASDAQ: HUMA) presents a compelling investment narrative. With a market capitalization of $429.68 million, this innovative healthcare..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds